drugset / Trial / NCT00880867

Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

NCT00880867

Phase 1 Terminated 3 enrolled Nevada Cancer Institute CLL Topics, Inc. · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objective of this study is to evaluate the safety of intratumoral Polyinosinicpolycytidylic acid stabilized with polylysine and carboxymethylcellulose (poly-ICLC)(Hiltonol®) in addition to low-dose local radiotherapy for adult patients with low grade lymphomas, including follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, chronic lymphocytic leukemia, and cutaneous T-cell lymphoma. The secondary endpoints are response rate, immune responses, and durability of responses as well as generation of antiinflammatory response at sites of tumor involvement.

Timeline

Start
2009-04
Primary completion
2010-05
Completion
2011-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified Other